Azenta life sciences partners with frenova, a division of fresenius medical care, and nephronomics to advance genomic research in nephrology

Burlington, mass. , july 31, 2025 /prnewswire/ -- azenta, inc. (nasdaq: azta) today announced that it has entered a collaboration with frenova, a division of fresenius medical care, and nephronomics, a renal precision medicine company, to begin genomic sequencing and data generation for frenova's transformative myreason® genomics research program.
AZTA Ratings Summary
AZTA Quant Ranking